We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Foghorn Therapeutics Inc (FHTX) USD0.0001

Sell:$12.60 Buy:$14.17 Change: $0.60 (4.22%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.60 (4.22%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.60 (4.22%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Foghorn Therapeutics Inc. is focused on the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. It is initially focused on oncology. It is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The Company is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

Contact details

500 Technology Square, Suite 700
United States
+1 (617) 5863100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$527.07 million
Shares in issue:
37.09 million
United States
US dollar

Key personnel

  • Adrian Gottschalk
    Chief Executive Officer, Director
  • Allan Reine
    Chief Financial Officer
  • Carl Decicco
    Chief Scientific Officer
  • Samuel Agresta
    Chief Medical Officer
  • Michael LaCascia
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.